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Alterations in the tumour suppressor p53 gene are among the most common defects seen in a variety of human 
cancers. In order to study the significance of the p53 gen in the genesis and development of human glioma 
from Indian patients, we checked 44 untreated primary gliomas for mutations in exons 5–9 of the p53 gene by 
PCR-SSCP and DNA sequencing. Sequencing analysis revealed six miss nse mutations. The incidence of p53 
mutations was 13×6% (6 of 44). All the six mutations were found to be located in the central core domain of 
p53, which carries the sequence-specific DNA-binding domain. These results suggest a rather low incidence but 
a definite involvement of p53 mutations in the gliomas of Indian patients. 
[Phatak P, Selvi S K, Divya T, Hegde A S, Hegde S and Somasundaram K 2002 Alterations in tumour suppressor gene p53 in human  
gliomas from Indian patients; J . Biosci. 27 673–678] 
1. Introduction 
Glioma, a neoplasm of neuroglial cells, is the most common 
type of brain tumour, constituting more than 50% of all 
brain tumours. Gliomas account for about 2% of the  
malignant tumours in adults. Malignant gliomas are the 
leading cause of central nervous system (CNS) tumour-
related death. Patients with glioblastoma have a life  
expectancy of less than one year even after surgery, 
chemo- and radiotherapy (Burger and Scheithauer 1993). 
The prognosis is even worse in children with brain stem 
malignant gliomas, the death occurring within 6–12 
months after diagnosis (Epstein and McCleary 1986). A 
better understanding of the biological pathway leading to 
glial tumourigenesis i  essential to arrive at new thera-
peutic modalities. 
 The p53 tumour suppressor gene is the most frequently 
altered gene in human cancer, including brain tumours. 
The p53 protein is a transcription factor involved in 
maintaining genomic integrity by controlling cell cycle 
progression and cell survival (Levine 1997; Somasundara  
and El-Deiry 2000). Consistent with this view, about 
50% of primary human tumours carry mutations in the 
p53 gene (Hollstein et al 1991; Levine et al 1991). The 
function of p53 is critical to the efficiency of many cancer 
trea ment procedures, because radiotherapy and chemo-
therapy act in part by triggering programmed cell death 
in response to DNA damage. Consequently, tumours 
which carry mutations in p53 are often difficult to treat, 
and their prognosis is poor. The characterization of the 
biochemical pathways by which p53 alteration triggers 
tumourigenesis is the foundation for the design of novel 
therapeutic approaches. 
 Karyotype analysis and restriction fragment length 
polymorphism (RFLP) analysis of glioma have shown 
several numerical and structural alterations of chromo-
somes (Bigner t al 1988; Libermann et al 1985; James  
et al 1988; Fujimoto et al 1989). One of the alterations 
frequently seen in glioma is LOH on chromosome 17p, 
which leads to deletion of the region that includes p53 
(Chung et al 1991; Frankel t al 1992; Fults etal 1992; 
von Deimling etal 1992; Ghosh et al 1994; Rasheed t al 
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1994; Jain et al 1999). Studies at many laboratories have 
shown that approximately 25% of the glioma carries  
mutations in p53 gene (Nigro et al 1989; Chung et al 
1991; Mashiyama et al 1991; Ohgaki et al 1991; Frankel 
et al 1992; Fults et al 1992; Saxena et al 1992; von 
Deimling et al 1992; Louis etal 1993). 
 In the study reported here, we tested 44 glioma sam-
ples from Indian patients for mutations in the p53 tumour 
suppressor gene by PCR-SSCP method. We found the 
p53 gene mutated in 13×6% (6/44) of the gliomas. 
2. Materials and methods 
2.1 Tumour samples 
Glioma tissue samples were obtained from patients who 
underwent surgery at Manipal Hospital, Bangalore, India. 
Forty-four patients with different grades of glioma were 
chosen for the study. Tissue samples were kept frozen at 
– 70°C. Total DNA was isolated from a part of the frozen 
samples. Tissue sections were used to identify the histo-
pathological grade and the type of glioma. 
2.2 Isolation of DNA 
A commercial DNA isolation kit (Qiagen, USA) was 
used to isolate genomic DNA from 25 mg of glioma tissue. 
2.3 Primers for PCR and DNA sequencing 
The primers used were oligonucleotides complementary 
to the sequence flanking the exon/intron juncti s of exons 
5–9 (Kovach et al 1991). The sequence of the primers is as 
follows: exon 5, 5¢-CTGACTTTCAACTCTG-3¢ (forward) 
and 5¢-AGCCCTGTCGTCTCT-3¢ (reverse); exon 6, 5¢-
CTCTGATTCCTCACTG-3¢ (forward) and 5¢-ACCCCA 
GTTGCAAACC-3¢ (reverse); exon 7, 5¢-TGCTTGCCACA 
GGTCT-3¢ (forward) and 5¢-ACAGCAGGCCAGTGT-3¢ 
(reverse); exon 8, 5¢-AGGACCTGATTTCCTTAC-3¢ 
(forward) and 5¢-TCTGAGGCATAACTGC-3¢ (reverse); 
exon 9, 5¢-TATGCCTCAGATTCACT-3¢ (forward) and 
5¢-ACTTGATAAGAGGTCC-3¢ (reverse). The same sets 
of primers were used for DNA sequencing. 
2.4 Polymerase chain reaction 
Genomic DNA (100 ng) was used for amplification in 
25 ml of reaction mixture. The composition of the 10X 
buffer used for all exons (except exon 7) was: 100mM 
Tris-HCl (pH 9×0), 15 mM MgCl2, 500 mM KCl, 0×1% 
gelatin. For exon 7, the composition was: 100 mM Tris-
HCl (pH 8×3), 35 mM MgCl2, 250 mM KCl. Each PCR 
re ction had a 1X PCR buffer, 100 mM dNTPs (Gibco 
BRL), 5 mCi a[32P]dATP, 5 pmol of each primer (Micro-
synth) and 0×5 U of Taq DNA polymerase (Bangalore 
Genei). PCR conditions for exon 5, 6 and 8 were 94°C 
for 5 min, 30 cycles of 94°C for 1 min, 57°C for 1 min 
and 72°C for 30 s and a final cycle of 72°C for 10 min. 
The condition for exon 7 was 94°C for 5 min, 30 cycles 
of 94°C for 1min, 65°C for 1 min and 72°C for 10 s, and 
a final cycle of 72°C for 10 min. The condition for exon 
9 was 94°C for 5 min, 30 cycles of 94°C for 1 min, 56°C 
for 1 min and 72°C for 15 s, and a final cycle of 72°C for 
10 min. 
2.5 Single strand conformation polymorphism analysis 
Labelled PCR products were checked for amplification 
by 2% agarose gel electrophoresis, diluted to 10 to 100-
fold in a loading and denaturing buffer (95% formamide, 
0×25% bromophenol blue, 0×25 xylene cyanol, 10 mM 
EDTA, pH 8×0 and 0×1 N NaOH), heated at 85°C for 
5 min and then subjected to single strand conformation 
polymorphism (SSCP) analysis using 6% non-denaturing 
polyacrylamide gel with 5% glycerol and 0×5X TBE as 
running buffer. Electrophoresis was carried out at 500 V 
for 3×5 h at 22°C for exons 5, 6, 7 and 9. For exon 8, the 
conditions remained the same, except that the gel was run 
at 15°C. Samples that showed band shifts were chosen 
for further study. 
2.6 Direct DNA sequencing 
Bands showing abnormal shifts in the SSCP analysis 
were purified from acrylamide gel using Microcon spin 
columns (Millipore) and used as templates to reamplify 
the fragment with the same set of primers originally used 
for amplification. The amplified DNA fragments were 
purified with a QIAquick PCR purification kit (Qiagen) 
and subjected to cycle sequencing (fmol cycle sequening 
kit; Promega) in both directions. Sequencing reactio s w re 
carried out in a thermal cycler under the following  
cycling conditions: 95°C for 2 min, 30 cycles of 95°C for 
30 s, 42°C for 30 s, and 70°C for 1 min. The samples 
were electrophoresed on a 6% polyacrylamide denaturing 
gel. Gels were dried under vacuum at 80°C, and exposed 
for Phosphor Imaging. 
 
3. Results 
3.1 PCR-SSCP analysis for detection of mutations 
PCR fragments generated from exons 5 t  9 of the p53 
gene were subjected to SSCP analysis. All 44 glioma 
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samples were checked for mutations. DNA samples 
showing mobility shifts or abnormal bands were scored 
as positive for mutation. Of the 44 samples analysed, six 
tumour DNAs showed an altered pattern in PCR-SSCP 
analysis (figure 1; table 1). Exon 5 analysis revealed the 
presence of mutation in samples G2 (figure 1a), G10 
(data not shown) and G20 (figure 1b). Sample 34 showed 
a differentially migrating band in exon 7 (figure 1c). 
Samples G23 and G33 (figure 1d) showed additional 
bands in exon 8 moving differently from normal bands. 
3.2 Identification of mutations by sequence analysis 
The bands that showed abnormal shifts in all the samples 
mentioned above were purified from gel and subjecte to 
DNA sequencing. The sequencing revealed the presence 
of mutation in all the six samples. Figure 2 shows the 
results of sequencing of some of the samples. Exon 5 of 
samples G2 and G10 had the same missense mutation 
(G–T), resulting in the conversion of valine to phenyla-
lanine at codon 172 (figure 2a). Exon 5 of sample G20 
had the missense mutation (T–G), resulting in the con-
version of valine to glycine at codon 173 (data not 
shown). Exon 7 of sample G34 showed the missense  
mutation (T–G), which convert d leucine to arginine at 
cod n 257 (data not shown). Exon 8 of G23 had the mis-
sense mutation (C–T), which caused the conversion of 
arginine to cysteine at codon 273 (figure 2b). G33 had 
the missense mutation (T–G) in exon 8, which resulted in 
the conversion of phenylalanine to cysteine at codon 270 
(figur  2c). 
4. Discussion 
The most frequent chromosomal abnormalities associated 
with glioma are gains of chromosome 7, losses of 10, 9p 
and 17p and EGFR gene amplification (Libermann et al 
1985; Bigner t al 1988; James t al 1988; Fujimoto et al 
1989). The loss of 17p is usually associated with muta-
tions in the p53 gene (Chung et al 1991; Frankel t al 
1992; Fults etal 1992; von Deimling et al 1992; Ghosh 
et al 1994; Jain et al 1999). The involvement of p53 in 
the development of glioma from Indian patients has been 
shown by loss of heterozygosity (LOH) analysis (Chatto-
padhyay et al 1997; Gosh etal 1994). The present study 
was carried out to determine the frequency of p53 muta-
tion in glioma derived from the Indian population. We 
analysed 44 glioma samples to check for mutations in 
 
Figure 1. PCR-SSCP analysis of glioma samples. The exons 5, 6, 7, 8 and 9 of p53 gene were ampli-
fied in the presence of a[32p]dATP using the total genomic DNA as template. The radiolabelled PCR 
products of exon 5 (a and b), exon 7 (c) and exon 8 (d) were run on a SSCP gel and autoradiographed. 
Only representative gels showing abnorm l bands in comparison to bands in the control lanes are shown. 
Arrows show the abnormal bands in exon 5 of sample G2 (a), G10 (not shown), G20 (b); exon 7 of 
sample G34 (c); exon 8 of sample G23 (d) and G33 (d). 
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exons 5–9 of p53 gene by the PCR-SSCP method. We 
found that 13×6% of the tumours tested positive for p53 
mutations (table 1). To our knowledge, ours is the first 
study of p53 mutation in glioma from the Indian populat o . 
 The central core of p53, which spans from amino acids 
100 to 300, contains the sequence-sp cific DNA-binding 
domain. This is the domain where majority of p53 muta-
tions have been found to occur. In our study, all six muta-
tions were mapped to this domain. 
The occurrence of p53 mutations in glioma has gener-
ally been associated with age. While the p53 alterations 
are rare among pediatric age groups, their incidence is 
high in young adults, and low among the older age group 
(Louis et al 1993; Rasheed t al 1994). This study shows 
that the incidence of p53 mutations amongst young adults 
(19–50 years) is 18% (5/27) and amongst patients > 50 
years old is 6×7% (1/15). No mutations of the p53 gene 
among the pediatric age group could be detected (0/2). 
Table 1. Details of glioma samples. 
                  
 
Sample 
Mutated 
exon 
 
Domain* 
 
Codon 
 
Base 
 
Amino acid 
 
Age/sex 
Histopathological 
grade 
 
Type**                   
G 1 – – –   46/M III  Anaplastic astrocytoma 
G 2 5 DBD 172 G to T Valine to Ph. alanine 32/M III  Anaplastic astrocytoma 
G 3 – – –   40/F III  Anaplastic astrocytoma 
G 4 – – –   48/M IV GBM 
G 5 – – –   53/M II Astrocytoma 
G 6 – – –   38/M II Oligoastrocytoma 
G 7 – – –   59/M IV GBM 
G 8 – – –   70/M IV GBM 
G 9 – – –   12/F II Pilocytic astrocytoma 
G 10 5 DBD 172 G to T Valine to Ph. alanine 68/F IV GBM 
G 13 – – –   38/F III  Anaplastic astrocytoma 
G 15 – – –   22/M III  Anaplastic astrocytoma 
G 17 – – –   68/M IV GBM 
G 18 – – –   21/F IV GBM 
G 19 – – –   36/M III  Anaplastic astrocytoma 
G 20 5 DBD 173 T to G Valine to glycine 43/M III  Anaplastic oligoastrocytoma 
G 21 – – –   46/F II Astrocytoma 
G 23 8 DBD 273 C to T Arginine to cysteine 30/M II Astrocytoma 
G 24 – – –   27/M II Astrocytoma 
G 25 – – –   58/F III  Anaplastic astrocytoma 
G 26 – – –   68/F IV GBM 
G 28 – – –   25/F III  Oligodendroastrocytoma 
G 29 – – –   22/M III  Anaplastic astrocytoma 
G 30 – – –   49/M IV GBM 
G 31 – – –   14/M II Astrocytoma 
G 32 – – –   27/M II Astrocytoma 
G 33 8 DBD 270 T to G Ph. alanine to cysteine 25/M II Astrocytoma 
G 34 7 DBD 257 T to G Leucine to arginine 37/M II Astrocytoma 
G 35 – – –   28/M IV GBM 
G 37 – – –   64/M IV GBM 
G 39 – – –   35/M IV Gemistocytic astrocytoma 
G 40 – – –   52/F IV GBM 
G 41 – – –   50/F IV GBM 
G 42 – – –   44/M IV GBM 
G 43 – – –   41/M III  Anaplastic astrocytoma 
G 44 – – –   52/M IV GBM 
G 45 – – –   35/M II Astrocytoma 
G 47 – – –   52/M IV GBM 
G 48 – – –   54/M IV GBM 
G 49 – – –   21/M IV GBM 
G 50 – – –   63/M II Pilocytic astrocytoma 
G 52 – – –   68/M III  Anaplastic astrocytoma 
G 53 – – –   55/M III  Anaplastic astrocytoma 
G 54 – – –   42/F IV GBM                   
*DBD refers to DNA binding domain of p53; **GBM refers to glioblastoma multiforme. 
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About 83% of the mutations were found in young adults 
(5/6), while only 17% were found in the older group 
(1/6). Thus our results confirm the relationship between 
p53 mutation and the age of the patient, as shown pre-
viously by others. Mutations of p53 were detected both in 
low-grade (grade II) and high-grade (grade III, IV) gliomas, 
wi h frequencies varying between 25 and 35% (Ohgaki  
et al 1995). Our results show that the p53 mutation fre-
quency is higher in low-grade gliomas than in high-grade 
gliomas. Grade II gliomas, which mainly comprise astro-
cytomas, had a frequency of 25% (3/12), while grade III 
gliomas, which are mainly anaplastic astrocytomas, had a 
frequency of 15×4% (2/13). In contrast to this, the p53 
mutation occurred at a low frequency of 5×4% (1/19) 
among grade IV glioblastoma multiforme cases. Three of 
the six p53 mutations were found in grade II gliomas. 
 Other mechanisms implicated in the abnormal func-
tioning of p53 are the amplification of MDM2 gene and 
the inactivation of p14ARF gene product. The binding of 
MDM2 protein to p53 results not only in the inhibition of 
p53-mediated transcription, but also in the rapid degrada-
tion of p53 (Oliner et al 1993; Haupt e  al 1997; Kubbu-
tat et al 1997). The binding of p14ARF to the MDM2 
protein inhibits the MDM2-mediated degradation of p53 
(Kamijo et al 1998; Stott et al 1998; Zhang et al 1998; 
Orlow et al 1999). Studies of the status of MDM2 and 
p14ARF genes in these glioma samples are currently in 
progress. 
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